Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH K HAN

Allopathic & Osteopathic Physicians Otolaryngology

NPI
1760577985
CMS profile
307434
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$280,830.98

236 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $112,952.87 63
Regeneron Healthcare Solutions, Inc. $50,502.64 53
GENZYME CORPORATION $45,225.55 38
Optinose US, Inc. $37,427.18 30
Medtronic, Inc. $12,403.98 14
Merck Sharp & Dohme LLC $7,819.76 10
AstraZeneca Pharmaceuticals LP $7,767.75 13
AERIN MEDICAL INC. $3,279.44 8
AstraZeneca UK Limited $1,879.50 1
PFIZER INC. $1,110.00 1
Regeneron Pharmaceuticals, Inc. $131.70 1
Grifols USA, LLC $127.82 1
Stryker Corporation $110.15 1
Genentech, Inc. $68.20 1
Phadia US Inc. $24.44 1

Page 4 of 5; records 151–200 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH K HAN

NPI 1760577985 · CMS profile ID 307434

Allopathic & Osteopathic Physicians / Otolaryngology

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760577985?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760577985?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760577985?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOSEPH K HAN, NPI 1760577985, CMS profile ID 307434, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760577985?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

236 matching records · $280,830.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 236 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 236.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $14.4204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202557 CMS
Regeneron Healthcare Solutions, Inc. $15.1704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202561 CMS
Regeneron Healthcare Solutions, Inc. $21.8604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202565 CMS
Regeneron Healthcare Solutions, Inc. $451.7404/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202569 CMS
Regeneron Healthcare Solutions, Inc. $23.5804/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202573 CMS
GlaxoSmithKline, LLC. $97.8604/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000914009 CMS
GlaxoSmithKline, LLC. $24.7704/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000914577 CMS
GlaxoSmithKline, LLC. $975.0004/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000913343 CMS
Merck Sharp & Dohme LLC $150.0004/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048497529 CMS
Merck Sharp & Dohme LLC $5,995.0004/03/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048497547 CMS
Merck Sharp & Dohme LLC $172.5503/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344355 CMS
Merck Sharp & Dohme LLC $55.7303/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344631 CMS
Merck Sharp & Dohme LLC $46.2203/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344635 CMS
Merck Sharp & Dohme LLC $59.7303/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344639 CMS
Medtronic, Inc. $6,975.0003/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1007478545 CMS
Merck Sharp & Dohme LLC $819.6503/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344359 CMS
Merck Sharp & Dohme LLC $149.3303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344407 CMS
Merck Sharp & Dohme LLC $199.0003/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048344643 CMS
Merck Sharp & Dohme LLC $172.5503/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048746047 CMS
Regeneron Healthcare Solutions, Inc. $3,384.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202537 CMS
Regeneron Healthcare Solutions, Inc. $7,896.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202541 CMS
Regeneron Healthcare Solutions, Inc. $3,384.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202545 CMS
Regeneron Pharmaceuticals, Inc. $131.7003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000014515 CMS
Optinose US, Inc. $140.9103/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035201173 CMS
Phadia US Inc. $24.4403/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 971745415 CMS
Regeneron Healthcare Solutions, Inc. $11.0003/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202523 CMS
Regeneron Healthcare Solutions, Inc. $11.9703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202527 CMS
Regeneron Healthcare Solutions, Inc. $3.1703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202531 CMS
Regeneron Healthcare Solutions, Inc. $23.5803/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202534 CMS
Medtronic, Inc. $25.0003/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329929 CMS
Regeneron Healthcare Solutions, Inc. $260.2103/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202507 CMS
Regeneron Healthcare Solutions, Inc. $264.7703/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202511 CMS
Regeneron Healthcare Solutions, Inc. $529.5403/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202515 CMS
Regeneron Healthcare Solutions, Inc. $661.9303/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202519 CMS
Optinose US, Inc. $1,500.0003/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035201711 CMS
Medtronic, Inc. $11.0003/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1007478549 CMS
Medtronic, Inc. $44.3103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329927 CMS
Medtronic, Inc. $21.4703/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329933 CMS
Medtronic, Inc. $39.4403/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329935 CMS
Optinose US, Inc. $1,200.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035201181 CMS
Optinose US, Inc. $17.7803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035201229 CMS
Regeneron Healthcare Solutions, Inc. $96.5803/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202503 CMS
Regeneron Healthcare Solutions, Inc. $267.7002/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202495 CMS
Regeneron Healthcare Solutions, Inc. $254.2002/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999202499 CMS
AstraZeneca Pharmaceuticals LP $29.9302/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014504405 CMS
Genentech, Inc. $68.2002/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040414573 CMS
AstraZeneca Pharmaceuticals LP $116.4702/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011567329 CMS
Medtronic, Inc. $454.4702/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329923 CMS
Medtronic, Inc. $32.3102/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026329925 CMS
GENZYME CORPORATION $600.2102/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049969481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $248,445.08 287
PY2020 $106,726.25 106
PY2021 $249,544.19 215
PY2022 $253,450.75 264
PY2023 $280,830.98 236
PY2024 $352,383.35 269
PY2025 $304,622.35 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,227.19 24
PY2025 Principal investigator $144,431.92 52
PY2024 Recipient $3,808.83 6
PY2024 Principal investigator $172,361.60 48
PY2023 Recipient $2,997.04 15
PY2023 Principal investigator $109,210.23 42
PY2022 Recipient $8,000.00 21
PY2022 Principal investigator $122,231.70 32
PY2021 Recipient $10,250.00 13
PY2021 Principal investigator $148,769.04 17
PY2020 Recipient $24,660.39 29
PY2020 Principal investigator $184,768.64 20
PY2019 Recipient $7,029.41 22
PY2019 Principal investigator $178,860.59 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,011.60 12/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149191
Principal investigator 1 SANOFI US SERVICES INC. $8,689.50 12/08/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087361
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,625.00 12/05/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MED SCHOOL
A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy No dispute reported 06/30/2026 1185547373
Principal investigator 1 GlaxoSmithKline, LLC. $2,507.40 11/25/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149170
Recipient GENZYME CORPORATION $500.00 11/06/2025 Covered Recipient Physician A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226120015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256953
Principal investigator 1 SANOFI US SERVICES INC. $3,299.00 10/20/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 10/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184245231
Principal investigator 1 GlaxoSmithKline, LLC. $1,504.80 10/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184807
Principal investigator 1 SANOFI US SERVICES INC. $6,146.50 09/22/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087278
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 09/03/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149174
Principal investigator 1 SANOFI US SERVICES INC. $16,128.00 08/25/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226087263
Principal investigator 1 SANOFI US SERVICES INC. $19,128.00 08/18/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087258
Principal investigator 1 GlaxoSmithKline, LLC. $422.10 08/04/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149187
Principal investigator 1 GlaxoSmithKline, LLC. $1,244.70 07/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184818
Principal investigator 1 SANOFI US SERVICES INC. $13,840.00 07/14/2025 Non-covered Recipient Entity
Old Dominion University
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226087230
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182778
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182786
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182790
Principal investigator 1 GlaxoSmithKline, LLC. $1,360.00 06/22/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182795
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 06/20/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149183
Recipient GlaxoSmithKline, LLC. $28.15 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182800
Recipient GlaxoSmithKline, LLC. $18.13 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182803
Recipient GlaxoSmithKline, LLC. $171.47 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192182808
Recipient GlaxoSmithKline, LLC. $76.71 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184788
Recipient GlaxoSmithKline, LLC. $128.47 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184792
Recipient GlaxoSmithKline, LLC. $64.27 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184796
Recipient GlaxoSmithKline, LLC. $102.09 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184800
Recipient GlaxoSmithKline, LLC. $888.81 06/19/2025 Covered Recipient Physician THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192184803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 06/18/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207861
Recipient SANOFI US SERVICES INC. $385.40 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119947
Recipient SANOFI US SERVICES INC. $652.80 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119952
Recipient SANOFI US SERVICES INC. $267.70 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119956
Recipient SANOFI US SERVICES INC. $50.00 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119962
Recipient SANOFI US SERVICES INC. $85.00 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119967
Recipient SANOFI US SERVICES INC. $69.81 06/06/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226119972
Recipient SANOFI US SERVICES INC. $200.17 06/05/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226119958
Principal investigator 1 GlaxoSmithKline, LLC. $422.10 05/21/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 05/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 05/19/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196997
Principal investigator 1 GlaxoSmithKline, LLC. $1,244.70 04/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 04/23/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184186031
Principal investigator 1 SANOFI US SERVICES INC. $11,414.46 04/21/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080661
Principal investigator 1 SANOFI US SERVICES INC. $1,610.00 04/07/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226080648
Recipient SANOFI US SERVICES INC. $788.36 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119976
Recipient SANOFI US SERVICES INC. $395.38 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119980
Recipient SANOFI US SERVICES INC. $395.50 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119983
Recipient SANOFI US SERVICES INC. $81.75 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119987
Recipient SANOFI US SERVICES INC. $21.80 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226119990
Recipient SANOFI US SERVICES INC. $275.12 03/03/2025 Covered Recipient Physician A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226119922
Recipient SANOFI US SERVICES INC. $536.15 03/03/2025 Covered Recipient Physician A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226119926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 02/27/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 02/27/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156042
Principal investigator 1 GlaxoSmithKline, LLC. $1,082.70 02/25/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184810
Principal investigator 1 GENZYME CORPORATION $3,029.60 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226080652
Principal investigator 1 GENZYME CORPORATION $3,000.00 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226080657
Principal investigator 1 SANOFI US SERVICES INC. $2,898.43 02/10/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) No dispute reported 06/30/2026 1226080637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 02/05/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152228
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,429.83 01/31/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MED SCHOOL
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185547371
Principal investigator 1 GlaxoSmithKline, LLC. $3,700.68 01/31/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCH
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192182782
Principal investigator 1 SANOFI US SERVICES INC. $4,198.75 01/27/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080640
Principal investigator 1 SANOFI US SERVICES INC. $2,790.00 01/27/2025 Non-covered Recipient Entity
Eastern Virginia Medical School Department Of Internal Medicine
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) No dispute reported 06/30/2026 1226080644
Principal investigator 1 GlaxoSmithKline, LLC. $1,752.30 01/24/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192149166
Principal investigator 1 GlaxoSmithKline, LLC. $1,875.00 01/08/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192184814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.60 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $770.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $280.80 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $539.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $539.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.40 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $308.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.00 01/02/2025 Non-covered Recipient Entity
EASTERN VIRGINIA MEDICAL SCHOOL
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144708
Recipient Regeneron Pharmaceuticals, Inc. $2,044.15 01/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184118185